| Objective:ShenfukangⅡcapsule on kidney interstitial fibrosis morphology and plasma levels of AngⅡin order to screen against kidney interstitial fibrosis and effective herbs, and set out against ShenfukangⅡin kidney interstitial fibrosis of the mechanism.Methods:Unilateral ureteral ligation method of manufacture of kidney interstitial fibrosis. 90 male SD rats were randomly divided into five groups: control group, model group, low dose group, middle dose group and high dose group, low dose group for ShenfukangⅡcapsule 200g/kg·d gavage, in dose of 400mg / kg·d fed, high-dose group800mg/kg·d fed, control group and model group at the same time each day to equal volume of normal saline. 7 days after administration, respectively, 14 days, 21 days to conduct modeling Masson staining of kidney interstitial fibrosis area change, measured by radioimmunoassay in plasma AngⅡlevels.Results:Masson staining compared: control group had no significant kidney interstitial fibrosis. compared with the control group, model group and treatment group there were significant changes in renal interstitial fibrosis (P<0.05); the treated group were significantly less compared with model group, with significant difference (P<0.05 ). Low-dose and high dose group, middle dose groups were significantly different (P <0.01); large, medium dose group had no significant difference (P> 0.05). RIA results showed that:The control group levels of plasma AngⅡwas no significant change in the model group and treatment group were significantly higher than the control group (P<0.05), but plasma AngⅡtreatment group were significantly lower than the model (P<0.05). Low-dose and high dose group, middle dose groups were significantly different (P<0.01); medium dose group and high dose treatment group, no significant difference (P> 0.05). Conclusion: This study shows that shenfukangⅡcapsule can delay kidney interstitial fibrosis. The way is by reducing the concentration of plasma AngⅡachieved.
|
PDF Full Text Request